Kymab: Biotech Company that is ‘One to Watch’

News   Sep 15, 2015

 
Kymab: Biotech Company that is ‘One to Watch’
 
 
 

RELATED ARTICLES

Therapeutic Avenue for Parkinson's Disease?

News

A new potential therapeutic avenue for Parkinson's disease. This research is unusual given that it focuses on senescence in astrocytes, so called "helper" cells that perform a variety of tasks, from axon guidance and synaptic support to control of the blood brain barrier and blood flow.

READ MORE

Cobra Biologics Awarded £2.6m ($3.4m USD) from Innovate UK

News

Capital infrastructure investment to embed and secure clinical and commercial viral vector manufacturing capability within the UK. Award made as part of UK’s Innovation Agency’s Industrial Strategy boost for UK medicines with £70m of funding to help develop new treatments.

READ MORE

‘Long Acting’ Nanomedicine for the Prevention Of Malaria

News

A new study, conducted by the University of Liverpool and the Johns Hopkins University School of Medicine highlights a new 'long acting' medicine for the prevention of malaria.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE